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ABSTRACT
Nowadays, more than 90% of patients affected by chronic myeloid leukemia (CML) survive with a
good quality of life, thanks to the clinical efﬁcacy of tyrosine kinase inhibitors (TKIs). Nevertheless,
point mutations of the ABL1 pocket occurring during treatment may reduce binding of TKIs, being
responsible of about 20% of cases of resistance among CML patients. In addition, the presence of
leukemic stem cells (LSCs) represents the most important event in leukemia progression related to
TKI resistance. LSCs express stem cell markers, including active efﬂux pumps and genetic and epi-
genetic alterations together with deregulated cell signaling pathways involved in self-renewal,
such as Wnt/b-catenin, Notch, and Hedgehog. Moreover, the interaction with the bone marrow
microenvironment, also known as hematopoietic niche, may inﬂuence the phenotype of surround-
ing cells, which evade mechanisms controlling cell proliferation and are less sensitive or frankly
resistant to TKIs. This Review focuses on the role of LSCs and stem cell niche in relation to response
to pharmacological treatments. A literature search from PubMed database was performed until
April 30, 2017, and it has been analyzed according to keywords such as chronic myeloid leukemia,
stem cell, leukemic stem cells, hematopoietic niche, tyrosine kinase inhibitors, and drug resistance.
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SIGNIFICANCE STATEMENT
The article deals with the revision of scientific literature on the role of leukemic stem cells
(LSCs) and stem cell niche in relation to the response to pharmacological treatments. Nowa-
days, current research focuses on LSC specific targets and novel drugs able to eradicate most or
all LSCs. Abnormal signaling pathways together with genetic and epigenetic alterations could
contribute to LSCs deregulation, to the development and progression of chronic myeloid leuke-
mia, and together contribute to the intrinsic resistance to tyrosine kinase inhibitors, supporting
the development of new therapies capable of eradicating specifically the LSCs.
INTRODUCTION
Involvement of Leukemia Stem Cells in
Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML), also known as
chronic myelogenous leukemia, is a myeloprolifer-
ative disorder arising from myeloid CD341/
CD38–/CD901 progenitors in the bone marrow
(BM) [1]. CML originates because of an incom-
plete process of differentiation of the hematopoi-
etic stem cells (HSCs) to adult cells and by an
accumulation of their immature form into the BM
and the peripheral blood (PB). CML disease is
characterized by the translocation of the Abelson
(ABL1) gene from chromosome 9 to the long arm
of chromosome 22, the Breakpoint Cluster Region
(BCR) [t(9;22)(q34;q11)], generating the so called
“Philadelphia chromosome.” This translocation
allows the constitutive activation of the fusion
oncoprotein BCR-ABL1, a tyrosine kinase (TK) acti-
vating different signaling pathways. The resulting
phenotype is characterized by an uncontrolled
proliferation, a reduced sensitivity to apoptotic
signals and production of an expanded progenitor
population known as cancer stem cells (CSCs) or
leukemia stem cells (LSCs). Indeed, the generation
of BCR-ABL1 fusion gene in a speciﬁc multipotent
HSC population may be sufﬁcient to initiate the
expansion of hematopoietic cell clones (HSCs-
granulocytic cell lineage), representing the ﬁrst
step in the genesis of CML, followed by the acqui-
sition of additional genetic mutations beyond
BCR-ABL1 [2].
The ﬁrst evidence of LSCs was proposed 20
years ago by Bonnet and Dick [3], based on the
idea that only a small subset of leukemic cells dis-
play self-renewal and long-term disease-propagat-
ing ability [3–6]. Nowadays, the presence of LSCs
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is partially associated with initiation, drug resistance and relapse
of CML. Although tyrosine kinase inhibitors (TKIs), such as imati-
nib, nilotinib, dasatinib, bosutinib, and ponatinib, have revolution-
ized the treatment of CML, offering survival rates higher than 90%
[7], at least 25% of patients show TKI resistance, more frequently
due to the presence of leukemic clones expressing ABL1 muta-
tions [8–14]. However, it has been demonstrated that persistence
of LSCs could be independent of BCR-ABL1 kinase activation [15,
16]. Overall, bilogical evidences suggest that curative approaches
in CML must focus not only on kinase-dependent mechanisms but
also on kinase-independent mechanisms of resistance [4], hence
offering the possibility to reduce the risk of disease relapse. Nowa-
days, current researches are focused on speciﬁc targets of LSC and
novel drugs are designed to eradicate the LSC population [17, 18].
These strategies include (a) targeting speciﬁc LSC surface markers
(b) modulation of signaling pathways (i.e., Wnt or Hh) able to
reverse LSC quiescence by interfering with the activity of tran-
scriptional factors (i.e., FoxO, BCL6, or PML), (c) interaction with
the hematopoietic niche, (d) inhibition of drug-efﬂux pumps (e.g.,
ABC transporters), (e) targeting differences in epigenetic regula-
tion between normal and LSCs (Fig. 1).
Identification of the LSCs
The isolation of LSCs from their normal counterparts is one of the
major challenges in CML. LSCs display cell surface markers similar
to those expressed by HSCs, including the expression of CD34,
Thy1/CD90, CD133, aldehyde dehydrogenase (ALDH) and several
lineage markers that characterize different types of mature cells
(Table 1) [5, 10, 11, 19, 20]. Despite the similarities between HSCs
and LSCs, recent studies identiﬁed new surface markers for LSCs,
such as the interleukin-1 receptor accessory protein (IL1RAP), and
the differential expression of already known markers, such as
Siglec-3 (CD33) and interleukin-3 receptor alpha chain (IL-3RA/
CD123), overexpressed in LSCs rather than HSCs [21–23]. LSCs
also express several surface markers relevant for LSC-niche inter-
action, such as CD44, CXCR4, and stroma cell-derived factor-1
(SDF-1) [24]. More recently, CD26, also known as dipeptidyl pepti-
dase IV (DPPIV), has been identiﬁed as a speciﬁc marker for
CD341/CD38– LSCs, together with IL-2RA (CD25) and CD52 [8,
25]. Indeed, CD26 is known as the target enzyme disrupting the
SDF-1-CXCR4-axis by cleaving SDF-1, thus facilitating the mobiliza-
tion of LSCs from the BM niche. On the contrary, this biomarker
was not detected in normal HSCs or in other hematopoietic malig-
nancies [8, 25]. Another phenotypic marker used to distinguish
HSCs from leukemic cells includes the ability to cause efﬂux of
Rhodamine-123 (Rho) and Hoechst 3342, which deﬁnes the so-
called Side Population (SP), characterized by the presence of
different members of the ATP-binding cassette (ABC) family of
transporters, including ABCB1/P-gp (P-glycoprotein) and ABCG2/
BCRP1 (breast cancer resistance protein 1) [19]. In particular, the
chemotherapy-resistant phenotype of LSCs is due to the presence
of a higher expression of ABCB1/P-gp, ABCC1/MRP1 (multi-drug
resistance related protein 1), LRP (lung-resistance protein), and
ABCG2/BCRP1 [26]. Moreover, in addition to SP phenotype, ALDH,
a cytosolic enzyme playing a key role in overall chemotherapy
resistance, may be considered another LSC marker [27]. Finally,
the high levels of BCR-ABL1 transcript in LSCs were found to be
linked to the autocrine secretion of IL-3 and G-CSF (granulocyte-
colony stimulating factor) that may induce the proliferation and
survival of CML progenitors, and contribute to their mobilization
through an increased secretion of chemokines such as CXCR12,
CCL2 (chemokine ligand 2) and CCL3/MIP-1a, compared with
HSCs.
Mechanisms of LSCs Self-Renewal Deregulation
Signaling Pathways in CML. Self-renewal deregulation has
been recognized as one of the most important events in leukemia
progression [28]. The aberrant activation of this feature is often
related to deregulated signaling pathways; indeed, their modula-
tion is considered a useful tool in CSCs research (Fig. 2) [29].
Wnt/b-catenin, Notch, and Hedgehog (Hh) are the most
important signaling pathways either in normal HSCs homeostasis
or in maintaining CML stem cells [30]. As a matter of fact, the dis-
ruption of differentiation and the enhancement of self-renewal in
CML progenitor cells is a critical component of disease progression
[31].
The Wnt pathway is crucial for HSC self-renewal and interac-
tion with BM niche, especially during the switch from chronic to
blastic phase (BP), and its activation has been associated with
the presence of the oncoprotein BCR-ABL1. When bound to its
receptor, Wnt ligand induces the inhibition of b-catenin phospho-
rylation by glycogen synthase kinase 3 b (GSK3b), and its cytoplas-
matic accumulation. The subsequent nuclear translocation of
b-catenin activates several transcription factors, such as LEF/TCF,
which expand the HSC pool [32]. On the contrary, LSCs have aber-
rant activation of b-catenin in BP-CML patients. Indeed, in both
K562 cells and in a CML murine model, BCR-ABL1 could stimulate
b-catenin through the inhibition of GSK3b mediated by phospho-
inositide 3-kinase (PI3K)/Akt signaling in blastic crisis (BC) of CML,
with an increase of leukemic burden and disease progression in
mouse model [33].
Notch signaling pathway is involved in the interaction among
leukemic, metastatic, and normal cells, and their native micro-
environment. Nakahara and coworkers reported that the Notch
Figure 1. Leukemic stem cells (LSCs) and potential targets of drug therapy.
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pathway plays an important role in advanced stages of CML [34];
the Hairy enhancer of split 1 (Hes1), a Notch target gene, in com-
bination with BCR-ABL1, was able to induce the BP in an in vivo
mouse model, with the consequent rapid death of animals. In
addition, Hes1 was highly expressed in 8 of 20 CML patients in
advanced stages, suggesting that Hes1 may be a key molecule for
the transition from chronic phase (CP) to BP [34]. Moreover, the
aberrant activation of another self-renewal pathway critical for
the maintenance of the LSCs during treatment with TKIs is Hedge-
hog (Hh), which is able to induce malignant expansion of LSCs in
an in vivo murine model, through a crosstalk with other pathways
[35, 36]. Hh signaling seems to be essential for CSC maintenance
in myeloid leukemia and the loss of the transmembrane protein
smoothened (SMO), an essential component of this pathway,
impaired HSCs renewal and decreased the induction of CML by
the BCR-ABL1 oncoprotein, whereas constitutively active SMO
was found to augment LSC number and accelerate the disease
[37]. In CML, BCR-ABL1 induces also the activation of PI3K/AKT/
mTOR pathway, resulting in a deregulated activity of several tran-
scription factors, including nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) and forkhead box class O
(FoxO). Members of the FoxO transcription factors (i.e., FoxO1,
3a, 4, and 6) are targeted for proteolysis via Akt-mediated signal-
ing [38], and play an important role in the maintenance of normal
HSCs and LSCs [39, 40]. Interestingly, the effect of BCR-ABL1 on
FoxO3a was also modulated via transforming growth factor-b
(TGF-b) signaling. In a mouse model of a CML-like myeloprolifera-
tive disease, Naka and collaborators showed that the nuclear
localization of FoxO3a, together with a decreased Akt phosphoryl-
ation in CML-CSCs, was associated with a decreased potential of
CSCs to promote malignancies, despite the expression of BCR-
ABL1 [40]. Several other proteins related to FoxOs, like the proto-
oncogene B-cell lymphoma 6 protein (BCL6), represent important
FoxO downstream effectors of self-renewal signaling in CML-
initiating cells [41]. In addition, BCR-ABL1 may activate multiple
down-stream pathways, including the Raf/MEK/ERK, SRC, and
JAK/STAT pathways [42, 43]. In a recent review, it has been
reported that Aurora kinase A (AURKA), through mechanisms of
phosphorylation of a series of genes (i.e., RASSF1A tumor suppres-
sor gene) and proteins (i.e., anti-apoptotic modulators Bcl-2 and
MCL-1 and pro-apoptotic regulators Bax, Bim, and PUMA), is
involved in the tumorigenesis of different hematological neo-
plasms (i.e., CML), and in the control of proliferation, epithelial-
mesenchymal transition (EMT) and metastasis, as well as self-
renewal ability of CSCs [44].
Many other genes are related to CML and stem cell mainte-
nance and transformation. The tumor suppressor protein phos-
phatase 2A (PP2A) could reduce the survival and self-renewal of
LSCs through BCR-ABL1 kinase-independent and PP2A-mediated
inhibition of Jak2 and b-catenin [45], whereas arachidonate 5-
lipoxygenase (5-LOX) gene (Alox5) and calcium-calmodulin-
dependent protein kinase II (CaMKII), are critical regulators for
LSCs in BCR-ABL-induced CML [46, 47]. Similarly, the tumor
suppressor promyelocytic leukemia (PML) gene has been also
identiﬁed as a regulator in the hematopoietic system and as
an important controller for stem cell maintenance and differentia-
tion [48].
Epigenetics in CML. Several studies showed that developmen-
tal pathways, including the polycomb-group protein (PGP), and in
particular BMI-1, play a role as epigenetic repressors implicated in
the regulation and expansion of LSCs during advanced phases and
in therapy resistance of CML [49–51]. In vitro results demon-
strated that the upregulation of BCR-ABL1 increased BMI-1
expression in CD341 cells of CML patients, suggesting that BMI-1
activity was controlled by BCR-ABL1 [52], and that BMI-1 cooper-
ated with BCR-ABL1 during disease progression [53]. In addition,
our group recently reported that BMI-1 expression increased in all
patients in the initial phases of treatment with imatinib, and that
its downregulation was associated with better responses to TKIs
and longer event-free survival (EFS) [54].
DNA methylation, histone modiﬁcation, and miRNAs also play
a signiﬁcant role in leukemogenesis: aberrant DNA methylation
could silence the expression of tumor suppressor genes in leuke-
mia, whereas the overexpression of histone methyltransferases
promotes oncogenesis (Table 2). Abnormal hypermethylation of
the ABL1 promoter represents an important marker of CML
pathogenesis associated with clonal evolution and disease pro-
gression [55]. For example, the methylation of additional genes,
such as the transcription factor AP-2 a (TFAP2a), the early B-cell
factor 2 (EBF2), the autophagy related 16-like 2 (ATG16L2), the
death-associated protein kinase 1 (DAPk1), and the cell cycle regu-
lating gene p15 (CDKN2B) was associated with progression, resist-
ance to TKIs, and a low probability to achieve MR3 (BCR-ABL1/
ABL1 ratio5 0.1% IS) at 18 months [56].
Histone modiﬁcations, including methylation and acetylation,
are involved in progression of CML; several pro- and anti-
apoptotic and cell cycle genes are targets of histone deacetylase
(HDAC) and histone acetyltransferases (HATs) in cancer cells [57].
Sirtuin 1 deacetylase (SIRT1) regulates the acetylation of several
transcriptional factors (i.e., TP53 and FoxOs) and consequently
plays an important role in the maintenance of normal and leuke-
mic SCs [58, 59]. Recently, it has been demonstrated that SIRT1
deacetylase is able to promote the acquisition of genetic muta-
tions implicated in drug resistance and survival of CML LSCs
Table 1. Cell markers that differentiate HSCs and LSCs
HSCs LSCs
CD25 (IL-2RA) – 1
CD26 (DPPIV) – 1
CD33 (Siglec-3) 1/– 1
CD34 1 1
CD38 (cyclic ADP ribose hydrolase) – –
CD44 (LHR) 1 1
CD47 1/– 1
CD52 1/– 1
CD71 (TfR1) – –
CD90 (Thy-1) 1 1
CD117 (c-KIT) 1 1
CD123 (IL-3RA) 1/– 1
CD133 (Prominin-1) 1 1
Speciﬁc Lineage Markers (Lin) – –
Aldehyde dehydrogenase (ALDH) 1 111
Side population (SP cells) 1 111
BCR-ABL1 translocation – 1
Abbreviations: DPPIV, dipeptidyl peptidase IV; HSCs, hematopoietic
stem cells; LSCs, leukemic stem cells.
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Table 2. Epigenetic mechanisms inducing leukemic stem cells (LSCs) deregulation
Role
Epigenetics Polycomb group proteins (PGPs) Involved in the regulation and expansion of LSCs during the CML
advanced phases
DNA methylations Signiﬁcant role in leukemogenesis.
Methylation of several genes (i.e., ABL1) are associated with progres-
sion of CML and resistance to TKIs
Histone modiﬁcations
(methylation and acetylation)
Signiﬁcant role in leukemogenesis and in CML progression (i.e., SIRT1)
Micro RNAs Signiﬁcant role in leukemogenesis.
miRNAs expression in CML patients reﬂect the disease progression
from the chronic to advances phases
Abbreviations: CML, chronic myeloid leukemia; SIRT1, sirtuin 1 deacetylase; TKIs, tyrosine kinase inhibitors.
Figure 2. The BCR-ABL pathway involves an intricate signaling networks including RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, TGF-b, WNT/b-cate-
nin, Hedgehog, and NOTCH. In the nucleus, the translocation from the normal chromosomes 9 to 22 generates the BCR-ABL hybrid gene, pro-
ducing the constitutively active tyrosine kinase oncoprotein. In the cytosol, the BCR-ABL protein, following recruitment of GRB2/GAB2/SOS
complex, stimulates the conversion of GDP-bound form of RAS in its active GTP-bound state. Therefore, the permanently activated RAS/RAF/
MEK/ERK pathway leads to an abnormal cell proliferation. In addition, the ignition of the PI3K/AKT/mTOR pathway causes both the activation
of mTOR and the inhibition of FOXO3, resulting in LSCs survival. This result is also promoted by the activation of TGF-b/SMAD4 way. Simulta-
neously, BCR-ABL supports the novel ALOX5 signaling pathway, suppressing the tumor suppressor gene PTEN. The inhibition of GSK3 main-
tained through the deregulation of both PI3K/AKT/mTOR and WNT/b-catenin pathways results in increased cytoplasmatic b-catenin levels
and, therefore, carcinogenesis. The progress of the disease in also correlated to Hh pathway, through the release of GLI transcription factor,
and NOTCH signaling through either the suppression of b-catenin phosphorylation by NICD or NICD inhibition by DSH. Abbreviations: ABL,
Abelson; AKT, v-Akt murine thymoma viral oncogene homolog 1; ALOX5, arachidonate 5-lipoxygenase; BCR, break point cluster region; DSH,
Disheveled; GSK3, glycogen synthase kinase 3; ERK, extracellular signal-related kinase; FOXO3, forkhead box O3; GAB2, GRB2-associated-
binding protein 2; GLI, glioma-associated oncogene; GRB2, growth factor receptor-bound protein 2; Hh, Hedgehog; IHh, Indian Hedgehog;
JAK2, Janus kinase; MEK1/2, mitogen-activated protein kinase 1/2; mTOR, mammalian target of rapamycin; NICD, Notch receptor intracellular
domain; PDK1, pyruvate dehydrogenase kinase 1; PI3K, phosphoinositide-3-kinase; PP2A, protein phosphatase 2A; PTCH, Protein patched
homolog 1; PTEN, phosphatase and tensin homolog; RAF1, rapidly accelerated ﬁbrosarcoma 1; RAS-GDP, RAS-guanosine diphosphate; RAS-
GTP: RAS-guanosine triphosphate; SHC, SHC-transforming protein; SMAD2/3/4, small mother against decapentaplegic 2/3/4; SMO, smooth-
ened; SOS, son of sevenless homolog; STAT5, signal transducer and activator of transcription; TGF-b, transforming growth factor beta.
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[60–62]. In an in vitro model, Wang and colleagues showed that
the inhibition of SIRT1 deacetylase by small molecule inhibitors or
gene knockdown blocks the acquisition of BCR-ABL1 mutations
and progression during treatment with TKIs [61]. The same
authors also demonstrated that SIRT1 silencing reduced and com-
promised the maintenance of LSCs in the BALB/c CML model
through an increased expression of cyclin-dependent kinase CDK6
and a reduction of TP53 expression [63].
Finally, miRNAs play a relevant role in CML. Machova Polakova
and colleagues identiﬁed differential expression proﬁles of several
miRNAs (miR-150, -20a, -17, -19a, -103, -144, -155, -181a, -221
and -222) in CML patients at different stages of disease, reﬂecting
the transformation from the chronic to advances phases of dis-
ease [64]. Interestingly, the target of miRNAs are proteins involved
in cell cycle, growth regulation, and signaling pathways related to
CML [64]. Analyzing these data, Ferreira and coworkers found that
TKIs (imatinib, nilotinib, and dasatinib) modulated the expression
of a series of different miRNAs in BCR-ABL1-positive cells obtained
from patients in different phases of CML including miR-let-7d,
-let-7e, -15a, -16, -21, -130a, -142-3p, and -145, with different
levels with respect to healthy subjects and according to the phase
of the disease [65]. In vitro, the long-term exposure of CML K562
cells to nilotinib and dasatinib induced drug-resistance in associa-
tion with increased levels of DNAmethyltransferase and downreg-
ulation of miR-217 [66]. On the contrary, miR-30e induced
apoptosis and sensitized CML K562 cells to imatinib via regulation
of the BCR-ABL1 protein [67]. In a recent work, the miRNA
expression proﬁle was assessed in different population of LSCs
(Lin- CD341 CD38- and Lin- CD34- CD38-), and showed that the
upregulation of miR-29a-3p and miR-660-5p in Lin- CD341 CD38-
CML LSCs, and downregulation of their respective targets TET2
and EPAS1, induces TKI-resistance. At the same time, miR-494-3p
downregulation was observed, leading to c-MYC upregulation,
and consequent TKI-induced apoptosis [68].
Taken together, these data demonstrate that several epige-
netic modulations of important genes play a critical role in the
pathogenesis of CML and in drug resistance to therapy. Since epi-
genetic changes have the potential to be modulated, they may
represent potential molecular tools to detect and treat cancer.
Nowadays, new drugs targeting different epigenetic mechanisms
are in development in several clinical trials or approved for speciﬁc
cancer types, including DNA methylation inhibitors, HADC inhibi-
tors, miRNA antisense oligonucleotides and miRNA mimics.
LSCs Interaction with the Hematopoietic Niche
In addition to the ABL1mutations, poor response to treatments is
often associated with quiescent LSCs located within the endosteal
region of the BM [69, 70]. Indeed, LSCs are capable of interacting
with the BM microenvironment, hence inﬂuencing the pheno-
types of surrounding cells, which acquire an increased prolifera-
tion potential and a reduced sensitivity or clear resistance toward
TKIs [71]. Indeed, there is evidence indicate that leukemic cells
can exploit physiological niche signals and overcome the control
by the normal microenvironment and/or can remodel BM niches,
supporting disease progression at the expense of the normal hem-
atopoiesis [72]. Generally, during normal hematopoiesis, a bidirec-
tional interaction between the niche and HSCs is required for the
maintenance of quiescence of normal BM stem cell. It is well
known that the BM microenvironment supports and regulates
the self-renewal, proliferation and mobilization of HSCs, through
cytokines, chemokines, and adhesion molecules [73]. These BM
cytokine networks are also important for HSC maturation, pluripo-
tency, and contact with immune cells. Generally, the BM niches
contribute positively or negatively to HSCs status. Several factors,
including the osteoblastic signaling molecule Jagged-1 [74], osteo-
pontin, and the chemokine (CXC motif) receptor 4 (CXCR4) and
ligand 12 (CXCL12 or SDF-1) are important for the proliferation,
apoptosis, trafﬁcking, and mobilization of HSCs to the BM, respec-
tively, [75–77]. Current evidence suggests that the HSC mobiliza-
tion by G-CSF is mediated by induction of BM proteases,
attenuation of functions of adhesion molecules, such as integrin
a4b1 (very late antigen-4, VLA-4), vascular cell adhesion
molecule-1 (VCAM-1), and disruption of CXCL12/CXCR4 signaling
in the BM [78]. In relation to CML, altered adhesion of leukemic
cells to the stroma was shown; indeed, Jin and colleagues demon-
strated that in CML, BCR-ABL1 activity is critical for the down-
regulation of CXCR4 expression, resulting in a defective adhesion
of CML cells to BM stroma [79]. Moreover, in the in vitro systems
of KBM-5 cells derived from a BC-CML patient cocultured with
BM-derived stromal cells (BMSCs), the restoration of CXCR4
expression by TKIs was associated with the increased migration of
CML cells [79]. It has also been found that CML cells may be able
to reduce functional CXCL12 expression in the surrounding cells,
to facilitate their egress from BM to other sites including spleen
and PB. Reduced CXCL12 expression in CML cells can also arise
from an additional mechanism. BM CML cells may exhibit
increased levels of several cytokines and chemokines including IL-
1a, IL-1b, IL-6, G-CSF, TNF-a, CCL3, and CCL4 [80]. Moreover, in
addition to chemokine receptors, integrins and other components
of the extracellular matrix have been implicated in the stroma-
mediated chemoresistance and hematopoietic cell homing
[81]. Other factors, such as the metallo-proteinase 9 (MPP9),
angiopoietin-1, and stem cell factor (SCF, also known as KIT ligand)
are instead involved in hematopoiesis and HSCs maintenance [82].
However, LSCs and normal HSCs appear to be differently regu-
lated by the microenvironment [80]. CML progenitors show an
altered interaction with the BM microenvironment and are in a
continuous state of proliferation due to deregulated functions of
important intercellular adhesion molecules on the LSCs surface
[83, 84]. It has been demonstrated that LSCs may alter the niche
secreting various costimulatory molecules and suppressive cyto-
kines that target metabolic pathways and create an anti-apoptotic
environment, thus facilitating the escape from immune surveil-
lance and inducing chemo-resistance. These cytokines include
CXCL12, SCF-1, interleukin-6 (IL-6), several growth factors such as
TGF-b, basic ﬁbroblast growth factor (bFGF), and vascular endo-
thelial growth factor (VEGF) [75]. During leukemogenesis, malig-
nant clones become progressively independent from the
physiological control of the niche. For example, the reduction of
JunB expression in LSCs diminishes the responsiveness of these
cells to Notch and TGF-b signals in the BM niche [85]. Moreover,
the quiescence and self-renewal of LSCs are strongly affected by
the leukemic niche. In particular, in a recent in vitro study, the use
of a conditioned medium obtained from a leukemic (REH) cell
line, enriched with IL-6 and IL-8, induced the loss of quiescence in
HSCs, increasing the proliferative stimulus. This phenomenon
could be related to several causes: (a) an increased expression of
cell proliferation-associated markers (i.e., Ki-67 and c-Myc), (b) an
upregulation of c-Kit, and (c) a downregulation of GATA2 and p53
proteins [86]. The effect of IL-6, together with TGF-a, has been
also demonstrated in newly diagnosed chronic phase (CP) CML
patients who subsequently received imatinib, suggesting that
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these cytokines may play a role as novel biomarkers. Indeed, their
high plasma levels were strongly predictive of subsequent failure
to achieve early and deep molecular response, transformation to
BP-CML and event-free survival [87].
The microenvironment can also contribute to leukemic sur-
vival and drug resistance through the release of exosomes, micro-
vescicles specialized to transfer a number of signals, including
immunosuppressive molecules and miRNAs in speciﬁc cells [88,
89]. Boyiadzis and coworkers suggested that tumor-derived exo-
somes can reprogram the BM environment, suppressing the anti-
leukemia immunity, and mediating drug resistance [88].
Cancer cells exploit several immunological mechanisms, such
as downregulation of target antigens, targeting regulatory T-cell
functions, or secretion of immune suppressive mediators. It has
been recently demonstrated that exosomes released by leukemic
cells may contain membrane-associated TGF-b1, which is able to
reduce the ability of natural killer (NK) cells to destroy the LSCs,
with the following induction of an immunosuppressive effect that
helps cancer cells to evade the immune response [89]. Raimondo
and colleagues found that CML-derived exosomes promote the
proliferation and survival of tumor cells, both in vitro and in vivo,
by activating anti-apoptotic pathways by a ligand-receptor interac-
tion between TGF-b1, present in CML-derived exosomes, and the
TGF-b1 receptor in CML cells [90]. Similarly, recent work demon-
strates that exosomes released from CML cells could stimulate
BM stromal cells to produce IL-8 that, in turn, is able to positively
modulate the malignant phenotype and survival of leukemia cells
both in vitro and in vivo [91]. Interestingly, increased IL-8 serum
levels have been found in hematologic malignancies compared
with healthy controls [92]. Moreover, an increased expression of
IL-8 and/or its receptors has been detected in cancer and stromal
cells suggesting the ability of IL-8 to modulate the tumor microen-
vironment. Taverna and colleagues found that miR-126 was over-
expressed in exosomes compared with parental cells. miR-126
induced a reduction of CXCL12 and VCAM1 expression in human
umbilical vein endothelial cells (HUVEC), and negatively modu-
lated the motility and adhesion of LAMA84 cells, suggesting that
exosomal miRNAs have an important role in tumor-endothelial
crosstalk occurring in the BM microenvironment, potentially
affecting disease progression [93]. Exosomes derived from both
LAMA84 cell lines and the plasma of CML patients contain amphir-
egulin (AREG), a member of the epidermal growth factor (EGF)
family. AREG has several functions, among which are (a) activation
of the EGF receptor signaling in stromal cells, (b) increased expres-
sion of SNAIL and its target MPP9 and IL-8, and (c) overexpression
of annexin A2, promoting the adhesion, growth, and invasiveness
of leukemic cells [94].
Hypoxia induces the expression of multiple pro-angiogenic
factors (i.e., VEGF, bFGF, and IL-8) in the tumor microenvironment;
it represents a common feature of myeloid malignancies, and is
able to inﬂuence LSCs cycling, quiescence, differentiation, metab-
olism, and therapy resistance. Hypoxia-induced VEGF production
in a mouse model of CML was found to be correlated with
increased clonogenicity, maintenance, repopulation capacity, and
resistance of BCR-ABL1 positive cells [95]. Moreover, when LSCs
hide themselves in the hypoxic BM niche, the BCR-ABL1 protein is
not synthesized despite the high levels of transcript, thus facilitat-
ing the resistance to TKIs.
BMSCs are an essential component of the HSC niche but they
are deregulated in a series of myeloid malignancies, including
CML. Recent studies, based on mice models of CML, demonstrate
that the speciﬁc interaction between BMSCs and leukemic cells is
important for leukemogenesis. BMSCs in CML failed to maintain
normal HSCs due to a reduction of CXCL12 expression and expan-
sion of LSCs. In addition, BMSCs secrete the placental growth fac-
tor (PlGF), which stimulate angiogenesis and promotes CML
proliferation and metabolism, increasing the disease aggressive-
ness in a manner partially independent from BCR-ABL1 signaling
[96].
Based on the above considerations, leukemia treatment
should target the microenvironment, and new biomarkers predic-
tive of treatment outcome should be developed to broaden treat-
ment opportunities.
Resistance to TKIs Mediated by LSCs
and Hematopoietic Niche
The introduction of TKIs in clinical practice has signiﬁcantly
improved the outcome of patients affected by CML. Nevertheless,
for several individuals, treatment must be discontinued or
changed due to the development of adverse drug reactions or
resistance. In CML patients, resistance may essentially develop
due to secondary BCR-ABL mutations, and/or BCR-ABL-
independent mechanisms, including the activation of signaling
pathways able to sustain the growth of progenitor LSCs (i.e.,Wnt/
b-catenin, Notch, PI3K, Hh), epigenetic control (i.e., polycomb
genes), and the activity of transmembrane transporters (i.e.,
inﬂux/efﬂux transporters).
One of the major causes of drug resistance is the altered func-
tion of the transmembrane transporters. Several members of the
ATP-binding cassette (ABC) transporters family are upregulated in
tumor cells [97] through the release of several factors by microen-
vironment. Indeed, the expression of ABC transporters is regu-
lated by a complex network of signals (i.e., transcription factors,
exosomes and epigenetic mechanisms), which allow the acquisi-
tion of the multi-drug resistant (MDR) phenotype [97–100].
Leukemic cells have an increased ability to pump drugs out of
the cells, due to the over-expression of transmembrane transport-
ers. The most widely studied ABC transporter members include
ABCB1/P-gp, ABCC1/MRP1 and ABCG2/BCRP. In normal HSCs,
these transporters play a relevant role in protection from genetic
damage exerted by toxic substances, and participate also in HSC
quiescence, differentiation and self-renewal, through the regula-
tion of cellular signaling effectors [101, 102]. Resistance to imati-
nib may be mediated by the over-expression of ABCB1 in K562
cells with loss of the inhibitory effect on cellular proliferation and
apoptosis [103], even if some contrasting results have been pub-
lished [104]. Studies of AP-CML patients treated with imatinib
have shown variations in the number of ABCB1-positive cells dur-
ing treatment, suggesting that TKI treatment causes selection of
LSCs characterized by the overexpression of transmembrane
transporters, together with other ABC members, such as ABCC1
and ABCG2 [104, 105].
The MDR phenotype may arise not only through the efﬂux of
ABC transporters, but also through several other phenomena such
as the reduction of drug inﬂux and imbalance in cell growth, sur-
vival, and death signaling. In addition to drug efﬂux, the uptake of
some TKIs into cells is dependent on membrane transporters,
such as the organic cation transporter 1 (OCT1) and the organic
cation/carnitine transporter 2 (OCTN2). Low expression of these
transporters induced a reduction of TKIs cytosolic concentrations,
playing an important role in therapeutic failure [106]. The expres-
sion proﬁle of inﬂux carriers was signiﬁcantly decreased in
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imatinib-resistant cell lines (i.e., K562-RC) with respect to the
parental K562 cell line [107]. Although those data strengthened
the role of transporters in response or resistance to TKIs, the cor-
relation among transporters, LSCs and TKIs resistance has not yet
been described.
As discussed in the above paragraphs, several factors may
contribute to the enhanced survival and growth of LSCs [36].
These cells have high BCR-ABL1 expression, and resistance may
arise from the inability of the drug to fully inhibit the BCR-ABL1
kinase activity. Indeed, TKIs have been described to inhibit the
oncogenic function in LSCs, without a complete eradication of the
disease due to the presence of intrinsic and acquired drug resist-
ance [9, 10]. Indeed, imatinib, nilotinib, and dasatinib efﬁciently
kill most CML cells, but cannot eliminate quiescent LSCs (CD341
CD38– CD45RA– CD71– HLA–), which are responsible for the pro-
gression of CML in patients who are diagnosed in advanced stages
of disease. Unfortunately, the relationship between the interac-
tion of LSCs with hematopoietic niche and resistance to TKIs is still
an unsolved issue.
Novel Chemotherapeutic Approaches for CML
The search for strategies to speciﬁcally target the LSC populations
are in development. New drugs such as DNA methylation inhibi-
tors (DNMTi, i.e., 5-aza-2-deoxycitidine or decitabine, hydralazine
and valproate) and HADC inhibitors (i.e., phenylbutyrate, romidep-
sin, entinostat, and vorinostat), are studied. In a phase I clinical
trial the effect of vorinostat and decitabine has been evaluated in
CML patients (NCT00275080). In addition, an open-label, phase I/
II study investigated the combined treatment of dasatinib and
decitabine in the control of CML disease (NCT01498445). More-
over, the efﬁcacy of panobinostat (LBH589) was evaluated in com-
bination with imatinib in inducing apoptosis in BC-CML CD341
cells, and in downregulating BCR-ABL1 levels (NCT00686218).
Similarly, the use of microRNA antisense oligonucleotides and
microRNA mimics have been also considered as potentially impor-
tant approaches to use in CML [108, 109].
In relation to new drugs targeting the signaling pathways, an
overview of the principal clinical trials is reported in Table 3. Tar-
geting components of these survival pathways, alone or in
Table 3. Signaling pathways and transcriptional factors deregulated in response to BCR-ABL1 activation
Pathway Role Effectors Inhibitors
Wnt/b-catenin  HSCs self-renewal
 Interaction with BM niche
 CML progression
Wnt
b-catenin
GS3K
Av65
Indometacin
Av65
SB216763
Notch  Interaction between leukemic,
HSCs, and BM niche
 CML advanced stages
gsecretase RO4929097
MK0752
Hedgehog (Hh)  Pathogenesis of CML SMO LDE225 (NCT01456676)
BMS833923 (NCT01218477;
NCT01357655)
PF04449913 (NCT00953758)
Cyclopamine
GDC0449
PI3K/AKT/mTOR  Normal hemopoiesis PI3K
AKT
mTOR1/2
NVP-BEZ235 (NCT01756118)
GDC0941
KU-0063794
Triciribine (NCT00642031)
NVP-BEZ235 (NCT01756118)
Rapamicin
KU-0063794
FoxO/TGF-b  Expression of genes involved in cell
growth, proliferation and
differentiation
 Involvement in BCR-ABL activated
PI3K/AKT pathway
TGF-b Ly364947
SB431542
JAK/STAT  Normal hemopoiesis
 Key player in a variety of myelopro-
liferative disorders
JAK 1/2 Ruxolitinib (NCT01914484;
NCT01751425)
AG490
TG101209
CYT387
ONO44580
ALOX5  Initiation and progression ALOX5 Zileuton (NCT02047149;
NCT01130688)
PML  Critical role in hemopoiesis
 Deregulated in CML
 LSC maintenance
PML Aresnic trioxide (NCT01397734;
NCT00006091; NCT00250042;
NCT00053248)
Arsenic sulﬁde
PP2A  Tumor suppressor protein downre-
gulated in CML LSCs in comparison
to normal HSCs
PP2A LB100
Abbreviations: CML, chronic myeloid leukemia; HSC, hematopoietic stem cells; PI3K, phosphoinositide 3-kinase; PML, promyelocytic leukemia;
PP2A, protein phosphatase 2A; SMO, smoothened; TGF-b, transforming growth factor-b.
Arrigoni, Del Re, Galimberti et al. 7
www.StemCellsTM.com Oc 2018 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
combination with TKIs, represents an attractive potential thera-
peutic approach against LSCs. However, many pathways are also
active also in normal stem cells.
The targeting of the Hh pathway, known to be activated in
CD341 CP-CML, through the inhibition of SMO using LDE225
alone or in association with nilotinib, was effective in reducing the
number and the self-renewal capacity of CML LSCs in vitro, with-
out effects on normal HSCs [110]. A phase I clinical trial investi-
gated the feasibility of administration of LDE225 with nilotinib in
patients with CML who have failed other TKI treatments
(NCT01456676).
Zileuton is an ALOX5 inhibitor, and in combination with imati-
nib showed an additive effect with prolonged survival in an in vivo
mouse model [46]. Based on these positive data, the safety of the
combined treatment zileuton plus imatinib has been evaluated in
a phase I study enrolling CML patients (NCT01130688). Clinical
phase 1/2 trials have been carried out in relation to arsenic triox-
ide (As2O3), a PML inhibitor. A phase 1/2 study has been devel-
oped to test the combined activity of As2O3 and imatinib in
treating patients who have CP-CML (NCT00053248). Similarly, a
more recent phase I clinical trial addresses the combination of
As2O3 with imatinib, dasatinib or nilotinib in CML patients
(NCT01397734). Starting from preliminary results, the approach
seems to be effective, but the toxicity and the effects on normal
HSCs needs to be monitored.
Several other drugs able to selectively inhibit signaling path-
ways are now in evaluation in preclinical models (Table 3) to
assess their capabilities to effectively eradicate CML stem cells
while sparing normal counterparts.
CONCLUSION
Unfortunately, we are still far away from the eradication of LSCs,
despite the long survival with a good quality of life in more than
90% of patients affected by CML. Indeed, gatekeeper mutations
of ABL1 may occur during the treatment with TKIs, thus interfering
with drug efﬁcacy, and LSC survival can be associated with about
20% of treatment failures. At the same time, the activation of the
oncogene BCR-ABL1 is responsible of the modulation of different
signaling pathways, which allow stem/progenitor CML cells to
evade cell death. Interestingly, epigenetic control could be rele-
vant to the survival of LSCs. BMI-1 is over-expressed in the
advanced phases of disease and correlates well with the clinical
outcome of CML patients. Furthermore, the hypoxic microenvir-
onment blocks the synthesis of the BCR-ABL1 protein, thus making
the LSCs resistant to TKIs. On the other hand, the BM niche is able
to hide the LSCs to the immune system through several mecha-
nisms. At the onset of disease, high levels of T-regs and suppres-
sive myeloid-derived suppressor cells, low numbers of NK, and the
activation of the immune check point system, prevent the
immune-dependent elimination of the LSCs. TKIs may ameliorate
the effect but they are not able to overcome it. However, the per-
sistence of LSCs is also independent of BCR-ABL1 kinase activa-
tion. Transmembrane transporters may play a relevant role for
both the excretion and uptake of drugs. LSCs may activate the
efﬂux pumps (i.e., ABC transporters), hence eliminating the TKIs,
while low-activity uptake transporters (i.e., hOCT1) may be associ-
ated with lower intracellular concentrations of imatinib and, con-
sequently, with a poor response to therapy.
Therefore, we know at least some fundamental mechanisms
that support LSC survival, and we are able to identify the CD341/
CD38–/CD901/CD261 CML LSCs also in the PB, even if recent
data have demonstrated the ability of CSCs to undergo dynamic
changes at the level of cell surface markers followed by epigenetic
regulations by the microenvironment.
Thanks to the huge steps forward in the treatment of CML,
several pathogenetic mechanisms responsible for the initiation
and survival of LSCs have been discovered, while others will be
investigated in the next years and will likely nourish the future
therapy of CML.
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